Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value
$108.52+1.27 (+1.18%)
Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%
Abbott Laboratories cash
Cash and short-term investments held at the end of each period.
Abbott Laboratories's cash was $4.30B at Sep 30, 2026. For fiscal 2025 it was $8.94B, up 12.2% from the year before. Over ten years it grew 3.9% a year on average. The highest annual figure on record is $18.78B in fiscal 2016.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.94B | +12.2% |
| FY2024 | Dec 31, 2024 | $7.97B | +9.5% |
| FY2023 | Dec 31, 2023 | $7.28B | -28.4% |
| FY2022 | Dec 31, 2022 | $10.17B | -0.8% |
| FY2021 | Dec 31, 2021 | $10.25B | +43.4% |
| FY2020 | Dec 31, 2020 | $7.15B | +72.7% |
| FY2019 | Dec 31, 2019 | $4.14B | +1.3% |
| FY2018 | Dec 31, 2018 | $4.09B | -57.5% |
| FY2017 | Dec 31, 2017 | $9.61B | -48.8% |
| FY2016 | Dec 31, 2016 | $18.78B | +206.5% |
| FY2015 | Dec 31, 2015 | $6.13B | +37.3% |
| FY2014 | Dec 31, 2014 | $4.46B | -44.9% |
| FY2013 | Dec 31, 2013 | $8.10B | -46.6% |
| FY2012 | Dec 31, 2012 | $15.17B | +87.4% |
| FY2011 | Dec 31, 2011 | $8.10B | +6.2% |
| FY2010 | Dec 31, 2010 | $7.63B | -31.1% |
| FY2009 | Dec 31, 2009 | $11.07B | +79.8% |
| FY2008 | Dec 31, 2008 | $6.15B | +118.1% |
| FY2007 | Dec 31, 2007 | $2.82B | +441.2% |
| FY2006 | Dec 31, 2006 | $521.19M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.30B | -44.4% |
| Q2 FY2026 | Jun 30, 2026 | $5.60B | -23.1% |
| Q1 FY2026 | Mar 31, 2026 | $7.30B | +6.6% |
| Q4 FY2025 | Dec 31, 2025 | $8.94B | +12.2% |
| Q3 FY2025 | Sep 30, 2025 | $7.73B | -0.7% |
| Q2 FY2025 | Jun 30, 2025 | $7.28B | +0.9% |
| Q1 FY2025 | Mar 31, 2025 | $6.84B | +2.9% |
| Q4 FY2024 | Dec 31, 2024 | $7.97B | +9.5% |
| Q3 FY2024 | Sep 30, 2024 | $7.79B | +10.5% |
| Q2 FY2024 | Jun 30, 2024 | $7.22B | -11.5% |
| Q1 FY2024 | Mar 31, 2024 | $6.65B | -30.2% |
| Q4 FY2023 | Dec 31, 2023 | $7.28B | -28.4% |
| Q3 FY2023 | Sep 30, 2023 | $7.05B | -28.9% |
| Q2 FY2023 | Jun 30, 2023 | $8.16B | -12.2% |
| Q1 FY2023 | Mar 31, 2023 | $9.53B | +16.8% |
| Q4 FY2022 | Dec 31, 2022 | $10.17B | -0.8% |
| Q3 FY2022 | Sep 30, 2022 | $9.91B | +2.2% |
| Q2 FY2022 | Jun 30, 2022 | $9.29B | +3.9% |
| Q1 FY2022 | Mar 31, 2022 | $8.16B | -2.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.25B | +43.4% |
| Q3 FY2021 | Sep 30, 2021 | $9.69B | +104.9% |
| Q2 FY2021 | Jun 30, 2021 | $8.94B | +77.6% |
| Q1 FY2021 | Mar 31, 2021 | $8.37B | +128.2% |
| Q4 FY2020 | Dec 31, 2020 | $7.15B | +72.7% |
| Q3 FY2020 | Sep 30, 2020 | $4.73B | +9.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.04B | +49.2% |
| Q1 FY2020 | Mar 31, 2020 | $3.67B | +12.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.14B | +1.3% |
| Q3 FY2019 | Sep 30, 2019 | $4.34B | -42.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.38B | +3.4% |
| Q1 FY2019 | Mar 31, 2019 | $3.26B | -19.3% |
| Q4 FY2018 | Dec 31, 2018 | $4.09B | -57.5% |
| Q3 FY2018 | Sep 30, 2018 | $7.55B | -32.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.26B | -66.8% |
| Q1 FY2018 | Mar 31, 2018 | $4.04B | -54.4% |
| Q4 FY2017 | Dec 31, 2017 | $9.61B | -48.8% |
| Q3 FY2017 | Sep 30, 2017 | $11.20B | – |
| Q2 FY2017 | Jun 30, 2017 | $9.84B | – |
| Q1 FY2017 | Mar 31, 2017 | $8.86B | – |
| Q4 FY2016 | Dec 31, 2016 | $18.78B | – |
See a number that looks wrong?